NRXP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
NRX Pharmaceuticals Inc (NRXP) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators show a bearish trend, and there are no significant positive catalysts in the short term. While analysts have raised price targets significantly, these are based on long-term FDA approvals expected in 2026, which may not align with the user's impatience for immediate returns. Additionally, the financials show improvement but remain negative overall, and there is no recent news or influential trading activity to suggest a strong near-term upside.
The stock is currently in a bearish trend with SMA_200 > SMA_20 > SMA_5. RSI is neutral at 38.8, and MACD is slightly positive but contracting. The pre-market price is $1.75, down 1.13%, and is near the key support level of $1.762. The stock has a 30% chance of declining further in the next day, week, and month.
Financials show YoY improvement in net income and EPS.
No recent news or influential trading activity. The stock is in a bearish technical trend, and pre-market price is declining. Financials remain negative despite YoY improvement. No recent congress trading data or Intellectia Proprietary Trading Signals.
In Q3 2025, revenue remained flat YoY at $242,000. Net income improved by 262.91% YoY but remains negative at -$5.89M. EPS improved by 73.33% YoY to -0.26. Gross margin remained stable at 49.17%.
Analysts are bullish on the stock with increased price targets ($45 and $48) and Buy ratings, citing long-term opportunities for NRX-100 and NRX-101 driven by FDA approvals in 2026.
